ASCO 2025 | IMMUNOSARC II: sunitinib & nivolumab in extraskeletal myxoid chondrosarcoma
Nadia Hindi, MD, Fundación Jimenez Diaz University Hospital, Madrid, Spain, discusses the Phase II IMMUNOSARC II trial (NCT03277924) of sunitinib with nivolumab in patients with advanced extraskeletal myxoid chondrosarcoma. The combination demonstrated promising clinical activity, with most patients achieving disease control at six months and a favorable progression-free survival. Adverse events were manageable and consistent with known profiles. This interview took place during the 2025 American Society of Clinical Oncology (ASCO) Meeting in Chicago, IL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
So in this Phase II study we included patients with advanced extraskeletal myxoid chondrosarcoma who were treated with sunitinib and nivolumab. The primary endpoint of the study was the progression-free survival rate at six months and this was a positive study because 77% of the patients were free of progression at this point. So we consider the study as positive based on the statistical assumptions...
So in this Phase II study we included patients with advanced extraskeletal myxoid chondrosarcoma who were treated with sunitinib and nivolumab. The primary endpoint of the study was the progression-free survival rate at six months and this was a positive study because 77% of the patients were free of progression at this point. So we consider the study as positive based on the statistical assumptions. The median progression-free survival of the patients exceeded one year. It was 13.2 months. And the median overall survival has not been reached yet, so with 90% of the patients alive at 12 months. So these are quite good results. In terms of toxicity, the regimen was quite well tolerated, was in line with what we have previously described in other cohorts of the CIVES study, and the grade 3 toxicities were mild, mainly due to transaminase elevations, but in any case there was not severe and there were no toxic deaths.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
